Page 74 - Multiple Sclerosis News Today

Results showed that evobrutinib did not produce a more superior reduction in annualized relapse rates than teriflunomide, a previously approved disease-modifying agent.

Among patients with multiple sclerosis who discontinue fingolimod, 10% experience a rebound, suggesting subsequent initiation of DMTs.

The Big Picture: Dr. Puja Uppal, Family Medicine, "If you have a high risk for Multiple Sclerosis, pay attention to these symptoms."Doctors Expert Insights About Autoimmune Conditions and Multiple Sclerosis

The Big Picture: Dr. Puja Uppal, Family Medicine, "If you have a high risk for Multiple Sclerosis, pay attention to these symptoms."Doctors Expert Insights About Autoimmune Conditions and Multiple Sclerosis

The Big Picture: Dr. Puja Uppal, Family Medicine, "If you have a high risk for Multiple Sclerosis, pay attention to these symptoms."Doctors Expert Insights About Autoimmune Conditions and Multiple Sclerosis

The Big Picture: Dr. Puja Uppal, Family Medicine, "If you have a high risk for Multiple Sclerosis, pay attention to these symptoms."Doctors Expert Insights About Autoimmune Conditions and Multiple Sclerosis

The Big Picture: Dr. Puja Uppal, Family Medicine, "If you have a high risk for Multiple Sclerosis, pay attention to these symptoms."Doctors Expert Insights About Autoimmune Conditions and Multiple Sclerosis

Worldsource Wealth Management to partner with Branch Out Neurological ...

The Big Picture: Dr. Puja Uppal, Family Medicine, "If you have a high risk for Multiple Sclerosis, pay attention to these symptoms."Doctors Expert Insights About Autoimmune Conditions and Multiple Sclerosis

The Big Picture: Dr. Puja Uppal, Family Medicine, "If you have a high risk for Multiple Sclerosis, pay attention to these symptoms."Doctors Expert Insights About Autoimmune Conditions and Multiple Sclerosis